Stockreport

Zenas Prepares For INDIGO Phase 3 Readout - Reinstating Buy Rating [Seeking Alpha]

Zenas BioPharma, Inc.  (ZBIO) 
PDF ZBIO's strong balance sheet, with $301.6M in cash and runway into late 2026, supports aggressive late-stage pipeline advancement. Obexelimab's positive Phase 2 MoonSt [Read more]